Poolbeg Pharmas #POLB – Results of Meetings June 23, 2025 – Posted in: Poolbeg Pharma (POLB) – Tags: POLB, poolbeg Pharma

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that all resolutions put to shareholders at the Company’s Annual General Meeting and General Meeting (together, the “Meetings”) held earlier today were duly passed. 

The voting results of the Meetings will be published on the Company’s website shortly:
https://www.poolbegpharma.com/investors/documents/ 

Admission and Total Voting Rights

Pursuant to the Company’s fundraising to raise total gross proceeds of £4.865 million, as initially announced on 20 May 2025, application has been made to the London Stock Exchange for 197,200,000 new ordinary shares to be admitted to trading on AIM. Admission is expected to occur, and dealings in the new ordinary shares are expected to commence, at 8.00 a.m. on 25 June 2025 (“Admission”).

Following Admission, the Company’s issued share capital will consist of 697,200,000 ordinary shares with voting rights. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 697,200,000 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Enquiries